$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023014920 Filed on May 02, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$13.24M	$11.13M
YoY Change	-0.18%	-9.26%
Cost Of Revenue	$6.617M	$4.737M
YoY Change	26.23%	12.41%
Gross Profit	$6.624M	$6.397M
YoY Change	-17.44%	-20.59%
Gross Profit Margin	50.03%	57.45%
Selling, General & Admin	$7.360M	$7.455M
YoY Change	-52.78%	-42.75%
% of Gross Profit	111.11%	116.54%
Research & Development	$3.473M	$3.547M
YoY Change	-33.19%	-25.69%
% of Gross Profit	52.43%	55.45%
Depreciation & Amortization	$250.0K	$286.0K
YoY Change	-61.83%	-59.94%
% of Gross Profit	3.77%	4.47%
Operating Expenses	$10.83M	$11.00M
YoY Change	-47.88%	-38.17%
Operating Profit	-$4.209M	-$4.605M
YoY Change	-67.02%	-52.71%
Interest Expense	$1.373M	$1.435M
YoY Change	-16.02%	-11.31%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$5.508M	$8.068M
YoY Change	-66.21%	-161.03%
Income Tax	$284.0K	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$5.792M	$8.068M
YoY Change	-64.47%	-161.03%
Net Earnings / Revenue	-43.74%	72.46%
Basic Earnings Per Share	-$0.10	$0.15
Diluted Earnings Per Share	-$0.10	$0.11
COMMON SHARES
Basic Shares Outstanding	55.92M shares	55.87M shares
Diluted Shares Outstanding	57.35M shares	73.79M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.44M	$26.88M
YoY Change	26.79%	82.42%
Cash & Equivalents	$22.44M	$26.88M
Short-Term Investments
Other Short-Term Assets	$1.301M	$2.292M
YoY Change	-20.53%	-31.05%
Inventory	$5.950M	$6.981M
Prepaid Expenses
Receivables	$10.10M	$7.551M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$39.79M	$43.71M
YoY Change	-8.54%	2.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.602M	$3.814M
YoY Change	0.72%	-15.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.469M	$6.485M
YoY Change	-7.26%	-5.82%
Total Long-Term Assets	$17.21M	$17.58M
YoY Change	34.37%	26.07%
TOTAL ASSETS
Total Short-Term Assets	$39.79M	$43.71M
Total Long-Term Assets	$17.21M	$17.58M
Total Assets	$56.99M	$61.29M
YoY Change	1.21%	8.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.69M	$12.44M
YoY Change	20.28%	46.42%
Accrued Expenses	$4.263M	$4.508M
YoY Change	-39.46%	-7.4%
Deferred Revenue	$3.992M	$4.765M
YoY Change	149.66%	198.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$18.36M	$17.20M
YoY Change	88.33%	162.0%
Total Short-Term Liabilities	$38.65M	$40.38M
YoY Change	30.43%	66.98%
LONG-TERM LIABILITIES
Long-Term Debt	$20.80M	$25.20M
YoY Change	-52.53%	-47.16%
Other Long-Term Liabilities	$2.006M	$2.059M
YoY Change	-15.68%	10.58%
Total Long-Term Liabilities	$2.006M	$2.059M
YoY Change	-15.68%	10.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.65M	$40.38M
Total Long-Term Liabilities	$2.006M	$2.059M
Total Liabilities	$163.6M	$170.5M
YoY Change	7.19%	13.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$308.9M	-$303.1M
YoY Change	7.9%	12.27%
Common Stock	$62.00K	$56.00K
YoY Change	16.98%	36.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$106.7M	-$109.2M
YoY Change
Total Liabilities & Shareholders Equity	$56.99M	$61.29M
YoY Change	1.21%	8.41%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$5.792M	$8.068M
YoY Change	-64.47%	-161.03%
Depreciation, Depletion And Amortization	$250.0K	$286.0K
YoY Change	-61.83%	-59.94%
Cash From Operating Activities	-$7.907M	$8.816M
YoY Change	20.5%	-160.88%
INVESTING ACTIVITIES
Capital Expenditures	$826.0K	$2.000K
YoY Change	-222.01%	-98.08%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$826.0K	-$2.000K
YoY Change	22.01%	-98.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.287M	-$9.205M
YoY Change	-57.96%	-809.17%
NET CHANGE
Cash From Operating Activities	-7.907M	$8.816M
Cash From Investing Activities	-826.0K	-$2.000K
Cash From Financing Activities	4.287M	-$9.205M
Net Change In Cash	-4.446M	-$391.0K
YoY Change	-250.25%	-97.06%
FREE CASH FLOW
Cash From Operating Activities	-$7.907M	$8.816M
Capital Expenditures	$826.0K	$2.000K
Free Cash Flow	-$8.733M	$8.814M
YoY Change	48.39%	-160.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001398733
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38599
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Aquestive Therapeutics, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Technology Drive
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Warren
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07059
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3827296
CY2023Q1	dei	City Area Code CityAreaCode	908
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	941-1900
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	AQST
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55922361	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26882000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27273000	usd
CY2023Q1	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	7551000	usd
CY2022Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	4704000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	6981000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5780000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2292000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2131000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	43706000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	39888000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3814000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4085000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5884000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5211000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1396000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1435000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6485000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6451000	usd
CY2023Q1	us-gaap	Assets Assets	61285000	usd
CY2022Q4	us-gaap	Assets Assets	57070000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12440000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9946000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4508000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7967000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	328000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	255000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4765000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1513000	usd
CY2023Q1	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1147000	usd
CY2022Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1147000	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	17195000	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	18700000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	40383000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39528000	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	25196000	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	33448000	usd
CY2023Q1	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	64137000	usd
CY2022Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	64112000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5706000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5085000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	33039000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	31417000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2059000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2034000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	170520000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	175624000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55922361	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55922361	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54827734	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54827734	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	56000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	55000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	193848000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	192598000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-303139000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-311207000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-109235000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-118554000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61285000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57070000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11134000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12270000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4737000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4214000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3547000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4773000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7455000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13021000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	15739000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	22008000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4605000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9738000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1435000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	1618000	usd
CY2023Q1	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	52000	usd
CY2022Q1	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	1861000	usd
CY2023Q1	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	14513000	usd
CY2022Q1	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	-3000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-353000	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8068000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13220000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8068000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13220000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55631947	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41465798	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73792886	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41465798	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-118554000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	344000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-8000	usd
CY2023Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-109235000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	913000	usd
CY2022Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-93143000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	325000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	727000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	344000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	913000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	56000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	40000	usd
CY2023Q1	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	0	usd
CY2022Q1	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	1836000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	260000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	100000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	2217000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	7678000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1201000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	591000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	195000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	230000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2494000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	182000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3472000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3963000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4874000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7602000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8816000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14482000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-104000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	916000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1298000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	9086000	usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
CY2023Q1	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1027000	usd
CY2022Q1	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9205000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1298000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-391000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13288000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27273000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28024000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26882000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14736000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1466000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1609000	usd
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26882000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-303139000	usd
CY2023Q1	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3507000	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2139000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	37804000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	32930000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11134000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12270000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11134000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12270000	usd
CY2023Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4122000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	3274000	usd
CY2023Q1	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3507000	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2139000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023Q1	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	38000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	669000	usd
CY2023Q1	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	7551000	usd
CY2022Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	4704000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	669000	usd
CY2023Q1	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	0	usd
CY2023Q1	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	49000	usd
CY2023Q1	aqst	Accounts Receivable Allowances Reclassifications AccountsReceivableAllowancesReclassifications	582000	usd
CY2023Q1	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	38000	usd
CY2023Q1	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	0	usd
CY2023Q1	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	38000	usd
CY2023Q1	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	793000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	669000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	1012000	usd
CY2022Q2	aqst	Pro Rata Portion Of Target Bonus ProRataPortionOfTargetBonus	280000	usd
CY2022Q2	aqst	Cash Payment Representing90 Days Of Base Pay CashPaymentRepresenting90DaysOfBasePay	150000	usd
CY2022Q2	aqst	Days Of Base Pay DaysOfBasePay	90	day
CY2022Q2	us-gaap	Severance Costs1 SeveranceCosts1	263000	usd
CY2022Q2	aqst	Number Of Installments NumberOfInstallments	3	vestingperiod
CY2022Q2	aqst	Severance Period SeverancePeriod	P18M
CY2022Q2	aqst	Coverage Duration CoverageDuration	P18M
CY2022Q2	aqst	Consulting Fee ConsultingFee	10000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1699000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1899000	usd
CY2023Q1	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	3359000	usd
CY2022Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	2914000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1923000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	286000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	714000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	967000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	6981000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5780000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46061000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46048000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	42247000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41963000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3814000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4085000	usd
CY2023Q1	aqst	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	418000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	108000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	419000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	96000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	903000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1230000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1266000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1300000	usd
CY2023Q1	aqst	Lessee Operating Lease Liability To Be Paid Year Four And Thereafter LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter	6319000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11018000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4984000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	6034000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2971000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2932000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1396000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1435000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	39000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13000	usd
CY2023Q1	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	5000000	usd
CY2022Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	5000000	usd
CY2023Q1	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1485000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1451000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6485000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6451000	usd
CY2023Q1	aqst	Number Of Guaranteed Royalty Payments NumberOfGuaranteedRoyaltyPayments	8	payment
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2407000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6389000	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	413000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	322000	usd
CY2023Q1	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	793000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	1012000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	895000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	244000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4508000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7967000	usd
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	usd
CY2023Q1	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	usd
CY2020Q4	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	12609000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	19487000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	10317000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	42413000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	42413000	usd
CY2023Q1	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2022Q1	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2909000	usd
CY2022Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	65259000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	52000	usd
CY2023Q1	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	0	usd
CY2023Q1	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	1147000	usd
CY2023Q1	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	65284000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55631947	shares
CY2016Q3	aqst	Number Of States That Brought A Lawsuit NumberOfStatesThatBroughtALawsuit	41	state
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41465798	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	18160939	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73792886	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41465798	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	344000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	913000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	344000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	913000	usd
CY2022Q3	aqst	Inducement Equity Common Stock Options Award Shares InducementEquityCommonStockOptionsAwardShares	100000	shares
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	usd

Files In Submission

Name	View Source	Status
0001628280-23-014920-index-headers.html	Edgar Link	pending
0001628280-23-014920-index.html	Edgar Link	pending
0001628280-23-014920.txt	Edgar Link	pending
0001628280-23-014920-xbrl.zip	Edgar Link	pending
aqst-03312023ex311.htm	Edgar Link	pending
aqst-03312023ex312.htm	Edgar Link	pending
aqst-03312023ex321.htm	Edgar Link	pending
aqst-03312023ex322.htm	Edgar Link	pending
aqst-20230331.htm	Edgar Link	pending
aqst-20230331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
aqst-20230331_def.xml	Edgar Link	unprocessable
aqst-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aqst-20230331_pre.xml	Edgar Link	unprocessable
aqst-20230331_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aqst-20230331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2023 Q2 Form 10-Q Financial Statement

#000162828023014920 Filed on May 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2023 Q2 Form 10-Q Financial Statement

#000162828023014920 Filed on May 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst